Future of human immunity: Ebola, Obesity and Vaccine Engineering
Details
Featuring: Barney S. Graham MD, PhD, Senior Investigator, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
Dr. Barney Graham is an immunologist, virologist, and clinical trials physician whose primary interests are viral pathogenesis, immunity, and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV), and emerging viral diseases. After graduating from Rice University, he obtained his MD from the University of Kansas School of Medicine in 1979. He then completed residency and two chief residencies in Internal Medicine, a fellowship in Infectious Diseases, and a PhD in Microbiology & Immunology at Vanderbilt University School of Medicine, where he rose to the rank of Professor of Medicine with a joint appointment in the Department of Microbiology & Immunology. In 2000 he became one of the founding investigators for the NIAID Vaccine Research Center at NIH where he is now the Deputy Director and Chief of the Viral Pathogenesis Laboratory. He is a member of the American Society for Clinical Investigation and the American Association of Physicians, and a Fellow of the Infectious Disease Society of America and the American Academy of Microbiology. He has authored more than 250 scientific publications and has been on editorial boards for the Journal of Biological Chemistry, Journal of Virology, Journal of Infectious Diseases, and Journal of AIDS. He serves as a consultant for organizations involved in vaccine development for HIV, Tb, malaria, RSV, and other pathogens. His laboratory investigates basic mechanisms by which T cells affect viral clearance and immunopathology, explores mechanisms of antibody-mediated viral neutralization, and develops vaccines to prevent respiratory virus infections.
Dr. Keith N. Haffer, President and Chief Scientic Officer, Braasch Biotech LLC
Dr. Haffer received his MS and PhD degrees from the University of Massachusetts in Veterinary Virology and Immunology. He subsequently completed post-doctoral training at Purdue University, School of Veterinary Medicine in Immunology and infectious diseases of swine. Dr. Haffer then held upper management positions with multi-national veterinary vaccine companies for 14 years, prior to starting his own consulting firm in 1994. His areas of expertise are viral, bacterial and mycoplasmal vaccines and adjuvants. He has directed product development leading to international registrations for vaccines in poultry, cats, dogs, cattle, pigs, goats and sheep.
Dr. Haffer is co-founder of Braasch Biotech LLC and serves as its President and Chief Scientific Officer. While at Braasch Biotech he has worked extensively on use of Anti-Somatostatin Vaccine for enhancing livestock productivity and therapeutic vaccine treatment of obesity. The work of Dr. Haffer and his co-inventors have resulted in multiple issued US and PCT patents on the technology and applications.
We are grateful to the generosity of New Work City (http://nwc.co/) for hosting/sponsoring this event.
Future of human immunity: Ebola, Obesity and Vaccine Engineering